Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [4][6]. Company Overview - Aquestive Therapeutics, Inc. is under scrutiny for allegedly providing false and misleading information regarding the approval timeline for its New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film [6]. - The company claimed confidence in the NDA submission and optimistic expectations for approval by the FDA's Prescription Drug User Fee Act (PDUFA) date of January 31, 2026 [6]. Legal Proceedings - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that the company concealed material adverse facts about the NDA, particularly regarding human factors in the use of its sublingual film [6]. Stock Performance - Following the announcement of deficiencies identified by the FDA in the NDA on January 9, 2026, Aquestive's stock price fell by more than 37% on the same day [7].

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Aquestive Class Action Lawsuit? Do you, or did you, own shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST)?Did you purchase your shares between June 16, 2025 and January 8, ...

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly providing misleading information regarding its New Drug Application for Anaphylm, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff if they suffered losses during the Class Period [2]. - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the NDA for Anaphylm [3]. Group 2: Regulatory Issues - On January 9, 2026, Aquestive announced it received a letter from the FDA identifying deficiencies that hindered labeling discussions for Anaphylm [3]. - The FDA's letter confirmed that the review of Anaphylm's NDA was ongoing, delaying approval beyond the January 31, 2026, Prescription Drug User Fee Act date [3]. Group 3: Company Background - Johnson Fistel, PLLP is a law firm specializing in shareholder rights and has recovered approximately $90.7 million for investors in previous cases [4].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. (AQST) due to allegations of misleading statements regarding the company's New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film, which led to significant stock price declines for investors [1]. Summary by Relevant Sections Allegations - The complaint claims that Aquestive provided investors with positive statements while concealing material adverse facts about the NDA for Anaphylm, particularly regarding human factors in the use of the sublingual film [1]. - The company minimized the significance of packaging, use, administration, and labeling issues related to Anaphylm [1]. Stock Price Impact - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026, marking a decline of over 37% in a single day [1]. Class Action Details - The class period for the lawsuit is defined as June 16, 2025, to January 8, 2026, with a deadline for shareholders to register for the class action set for May 4, 2026 [1]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false and misleading statements regarding the approval timeline for Anaphylm, leading to artificially inflated stock prices [4]. Group 2: Stock Price Impact - Following the announcement on January 9, 2026, regarding deficiencies identified by the FDA in the NDA for Anaphylm, Aquestive's stock price dropped by more than 37% on the same day [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Aquestive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for Anaphylm (Dibutepinephrine) sublingual film, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [1][4]. Group 1 - The lawsuit is on behalf of investors who acquired securities of Aquestive Therapeutics during the specified period [1]. - Interested parties can submit a form or contact the Investor Relations Manager for more information regarding the lawsuit [2]. - A lead plaintiff must file papers by May 4, 2026, to represent the class in the litigation [3]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigation [5].